SCHEMBL4152708

SCHEMBL4152708

CN(C)CCNc1ccc(-c2nc3c(C(=O)NC45CCC(CC4)C5)ccnc3[nH]2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.39
UHRF1 Q96T88 1/20 0.39
GSK3B P49841 5/20 0.33
PBK Q96KB5 3/20 0.33
CNR2 P34972 6/20 0.32
PIK3C3 Q8NEB9 1/20 0.32
PARP1 P09874 1/20 0.32
AKT3 Q9Y243 1/20 0.32
CDC7 O00311 1/20 0.31
CDK19 Q9BWU1 1/20 0.31
KDM4E B2RXH2 1/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
WNT1 P04628 1/20 0.31
CLK2 P49760 1/20 0.31
CLK3 P49761 1/20 0.31
DYRK1A Q13627 1/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4157398 0.85 CNR2 (0.36) CNR2PARP1CNR1
SCHEMBL4159185 0.84 GSK3B (0.40) GSK3BPBKCNR2PARP1CNR1
SCHEMBL4152887 0.83 CNR2 (0.42) GSK3BCNR2KDM4ENPC1RAB9A
SCHEMBL4164560 0.83 RAD52 (0.42) RAD52UHRF1GSK3BCNR2PARP1
SCHEMBL4144891 0.82 RAD52 (0.42) RAD52UHRF1PBKCNR2KDM4E
SCHEMBL13778206 0.80 ALDH1A1 (0.40) RAD52UHRF1GSK3BPBKCNR2
SCHEMBL13778203 0.80 ALDH1A1 (0.40) RAD52UHRF1GSK3BPBKCNR2
SCHEMBL4159072 0.80 TDP1 (0.41) RAD52UHRF1GSK3BPBKPARP1
SCHEMBL4961738 0.80 RAD52 (0.43) RAD52UHRF1GSK3BPARP1KDM4E
SCHEMBL4152290 0.80 RAD52 (0.44) RAD52UHRF1GSK3BPARP1CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 RAD52 4618/4885UHRF1 3834/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.